investors & media

There are currently no events to display.

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases

6/12/2020

89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β 0 /β 0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207 Data from exploratory analyses of HGB-207 show improved markers of blood

Read more
6/12/2020

99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up At up to 24 months, no reports of serious VOC or ACS in Group C patients (n=18) with at least six months

Read more
6/3/2020

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, to support the health and well-being of its directors, employees and stockholders, the

Read more